Guidelines in SUDDEN SENSORINEURAL HEARING LOSS

Thierry MOM CLERMONT-FERRAND (France) IFOS COURSE HO CHI MIN CITY NOVEMBRE 2019



CLERMONT FERRAND

DEFINITION AND BACKGROUND

- SUDDEN SENSORINEURAL HEARING LOSS \geq 30dB
- EXCLUDE ALL CASES OF ACTIVE OTITIS MEDIA
- THE CAUSE IS MOST OFTEN UNKNOWN
- 45-55 YO M \approx F, NORMAL TYMPANIC MEMBRANE
- WITH OR WITHOUT VERTIGO
- SPONTANEOUS RECOVERY CAN OCCUR
 - 1/3 OF CASES FOR Ortman and Nelly 2012
 - SOMETIMES LATE SPONTANEOUS RECOVERY: 9 MONTHS (Ortman and Nelly 2010)





DEFINITION AND BACKGROUND

- SEVERITY OF INITIAL SNHL IS CORRELATED WITH PROGNOSIS
 - THE POORER THE HEARING, THE POORER THE CHANCE OF RECOVERY
- THIS HETEROGENICITY MAKES THE ANALYSIS OF OUTCOME DIFFICULT TO ACHIEVE AND THE THERAPEUTIC RATIONALE DIFFICULT TO CHOOSE
- AT IFOS MEETING IN PARIS (2017) AN ATTEMPT OF CONSENSUS HAS BEEN DRAWN: INSISTING ON THE HETEROGENICITY OF CAUSES RENDING
 DIFFICULT THE MANAGEMENT







FIRST IMPORTANT QUESTION: WHICH PART OF THE AUDITORY PATHWAY IS ALTERED?

- Huge heterogenicity of causes due to the different deleterious mechanisms
- COCHLEA: Stria vascularis, organ of Corti (OHCs or IHCs), membranes and gap junctions, homeostasis of fluids (hydrops)
- SYNAPTIC RIBBON
- ACOUSTIC FIBERS
- CENTRAL PATHWAYS





THE COCHLEA







WHICH EXPLORATIONS? First: AUDIOLOGIC TESTING



Clermon

Auverane

PTA but also speech discrimination An approx. same level of hearing loss can be associated with a quite different discrimination

For example here: lack of tuning (OHCs)? Or acoustic distortion due to acoustic fibers dysfunction



Acoustic facial reflex

- If there is no facial paralysis, and SNHL: excellent test of the acoustic nerve.
 - Absence of AFR suggests alteration of acoustic nerve
 - Presence of AFR is likely due to alteration of cochlea
- Even though it is not very specific, it is a noninvasive test very simple to achieve





Auditory Brainstem Responses (ABRs)



AUDIOMETRIE VOCALE







PEA Gauche

- Test the whole peripheric auditory function
- Here, in moderate SNHL, likely point to alteration of acoustic nerve



0



Otoacoustic emissions - OAEs

- Generated by OHCs
- Presence of OAEs in case of SNHL suggests:
 - Either a simulator
 - Or a retrocochlear cause without ischemia
 - Fine analysis of phase spectrum: hydrops







WHAT ABOUT VESTIBULAR FUNCTION?

- SAME BLOOD SUPPLY:
- DELAY VERTIGO: sudden deafness followed by BPPV preceding brainstem infarction
- Sensitive to same virus (VZV, Ramsay Hunt syndrome, Sicard syndrome)
- Same peripheric nerve pathway: cochlear vestibular nerve : alteration of one nerve can altered function of the other.













Shared blood vessels

same nerve pathway

[Anatomy of the vestibulo-acoustico-facial neurovascular pedicle. Importance of therapeutic management of vestibular schwannomas].

Mom T, Gabrillargues J, Gilain L, Chazal J, Kemeny JL, Vanneuville G. Neurochirurgie. 2002 Nov;48(5):387-97. Review. French.





CARDIOVASCULAR EXPLORATION

- Kim JY et al, 2018: JAMA oto: [OR =2.02; CI 95%; 1.16-3.51] to have stroke compared to controls, after SNHL in long follow-up
- FORAMEN OVALE: heart echography
- CARDIAC ARYTHMIA: electrocardiogram
- THROMBOSIS (VERTEBROBASILAR SYSTEM): echogaphy or angiography of supra aortic arteries
- AUTO-IMMUNE ANTIBODIES (ANTI PHOSPHO LIPID): serum level





IMAGING: very important Bilateral vestibular schwannoma revealed by LEFT sudden SNHL (deafness)



IMAGING



LEFT SUDDEN DEAFNESS : INFECTIOUS LABYRINTHITIS MRI Axial Flair T1 WITH GADOLINIUM: HIGH SIGNAL OF LANYIRNTHINE STRUCTURES







LEFT SUDDEN DEAFNESS : INFECTIOUS LABYRINTHITIS MRI 3D T2: LOSS OF LABYRINTHINE FLUID SIGNAL





MANAGEMENT of sudden SNHL

- FIRST : confirm sudden SNHL and try and spot the altered site
 - audiologic explorations
 - Vestibular explorations
 - Cardiologic investigations
 - Dedicated imaging (MRI, sequences T1 flair)
 - Exhaustive inflammatory blood work
 - IMAGING: CEREBRAL and CPA MRI AND
- SECOND: Importance of early treatment: functional exploration must not delay treatment onset





SUDDEN SNHL	FUNCTIONAL EXPLORATION	
PTA AND SPEECH DISCRIINATION	ALWAYS	
REFLEXE ACOUSTICO FACIAL REFLEX	ADVISED	MODERATE SNHL
ABRs	ALWAYS	
OEAs / (ECOG)	ALWAYS	ACOUSTIC PHASE SHIFT (fluctuation of SP/AP)
MRI	ALWAYS	T1 /T2/ GADO/ FLAIR
CARDIOVASCULAR EXPLORATION	ALWAYS	
SYSTEMIC BLOOD WORK	ALWAYS	SPECIALIST INTERNIST
SEARCH FOR INFECTION VIRAL OR BACT	IF CLINCAL SUSPICION	





ETIOLOGIES

- Possible causes are numerous:
 - Vascular accident:
 - Infllammatory process
 - Auto-immun disease
 - Tumor
 - Genetics: revelation of cochlear fragility





TREATMENT

- CORTICOIDS: reference even though there's no strong evidence proving their efficacy
- Clinical Practice Guideline of the AAO-HNS
 - Vasoactive drugs, thrombolytics, antioxydants ou antiviral drugs have no evidence of effectiveness

Stachler et al. Otolaryngol Head Neck Surg 2012





Rationale for corticoids in sudden SNHL

- Most of etiologies can respond to corticoids
- Oral administration is simple (but side effects possible)
- Clinical series seems to show that corticoids are effective
 - Evidence limited by heterogenicity of population (etiologies)
 - Dose-effect might have an impact on outcome
 - Intratympanic treatment is rather recent but seems to be effecitve
- Other treatments? transtymapnic genic thérapy?





PRACTICAL GUIDELINES FOR USE OF CORTICOIDS

- SYSTEMIC ADMINISTRATION: &MG/KG/D 7-10 DAYS (NOT IN DIABETES PATIENTS)
- OR INTRATYMPANIC: 1-5 CONSECUTIVE ITT
- OR BOTH





ITT: HOW TO DO IT IN ROUTINE PRACTICE

Local Anesthesia, oxybuprocaïne +/- Bonain Needle for Lumbar puncture long enough, to bend it

Myringotomy: large, radial, postero-inferior -Air of cavum tympani will be chase out of the ear through the large myringotomy during ITT -TM closed in 5-7 d



Patient in decline position, No swallowing for 10-30 mins. 5 ITT (1/d) consecutive





Intratympanic treatment (ITT)

- corticoids
 - Déxaméthasone
 - Méthylprednisolone: PLUS DL
- ITT of corticoids:
 - in case of failure of oral corticoids (salvage treatment)
 - In case of contraindication to systemic steroids
 - In case of severe to profound deafness





ITT or systemic corticoids first

Rauch et al. JAMA 2011: prospective, multicentric, randomized study; ≥18 yo; M/F 1,5/1. < 14 jours

Groupe	Oral	ITT		
Treatment	Prednisone 60mg/d for 10d then 5d regression	4 ITT méthylprednisolone 40mg/ml i 2 weeks		
n	121	129		
PTA thresshold	86,7 dB	86,4 dB		
% discrimination	14,0%	15,9%		
Recovery \leq 30 dB	20,7%	24,8%		
recovery 30-90 dB	66,9%	62,0%		
NO recovery (< 10 dB)	15,7%	23,3%		
Average recovery	30,7 dB	28,7 dB		
Side Effects	Mood alteration, sleep disorders, appetite, 个Na+, oral dryness,个 body weight	Otalgia, pain during ITT, vertigo, infection, tympanic membrane perforation (3,9%)		
Cost	<\$10	\$ 688 (+4 consultations, transportation, inconfort)		

What about combined treatment?

- Battaglia et al. Otol Neurotol 2014
 - prospective, multicentric (n=139), SNHL (class C or D) < 42d
 - Treatment
 - 2004-2007 (n=59): oral corticoids ($60 \text{mg/d} \times 7 \text{d}$ then \downarrow during 7d)
 - 2008-2012 (n=80): combined Treatment (oral idem + ITT DXM 10mg/ml 3 ITT /week)

Group	Oral corticoids ≤ 7d (mean 3.6 d)	combined corticoids ≤ 7d (mean 3.6 d)	Oral corticoids > 7d (mean 16.6 d)	combined corticoids > 7j (moy 16.6 d)
PTA gain	17,6 dB	39,8 dB	4,4 dB	20,0 dB
discrimination gain	29,3 % P < (5 8,4 %	6,3 %	28,7 %
post treatment class	C	В	D	D

 \Rightarrow combined corticoids more effective than coral corticoids \Rightarrow Effectiveness depends on delay of treatment

What about combined treatment?

• Demirhan H, et al. Contribution of intratympanic steroids in the primary treatment of sudden hearing loss. *Acta Otolaryngol. 2018*;138(7):648-651.

Groupe	Oral corticoids (n=144)	C	Combined treatment (n=60)		
Complete recovery	34%	<i>P</i> = 0,004	55%		

• Best recovery if SNHL is severe

What about combined treatment?

- **TSOUNIS M, et al.** Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial. *Eur Arch Otorhinolaryngol. 2018*;275(1):103-110.
 - N=102, treatment < d 14

Groupe	IV then oral corticoids (n=35)		ITT (n=34)		Combined treatment (n=33)	
Gain en tonale	29 dB	<i>P</i> > 0,05	27 dB	<i>P</i> > 0,05	29.8 dB	

No significant effect (iv administration? Heterogenicity of etiology?)

What about ITT of corticoids in salvage cases?

- Moon et al. Otol Neurotol 2011
 - prospective, multicentric, randomized in 3 groups after oral corticoids failure (60 mg prednisolone) : 151/415 = 36%
 - Control Group: oral corticoids
 - Group oral « corticoids »: same 2nd protocol of oral corticoids
 - Group DXM ITT : 5 injections of 5mg/ml un ITT every 2d s

at 2 weeks of initial treatment

• Results at 2 months :

Groupe	improvement	Amount of recovery
Control	15,4 %	5,5 dB
Oral corticoids	16,9 %	5,7 dB
ITT	48,5 %	<i>P</i> < 0,05 14,3 dB

\Rightarrow	ITT	is	more	effective	in	salvage
	trea	tm	ient			

4^{ème} question : Quel est l'intérêt des ITT en rattrapage?

- Zanetti D, et al. Intratympanic steroid delivery by an indwelling catheter in refractory severe suddensensorineural hearing loss. *Auris Nasus Larynx. 2018*;45:227-233.
 - Prospective case- control
 - Oral corticoids (n=99) and salvahge ITT (DXM 4mg/j x 7d) (n=28)
 - Gain in PTA : 75% if ITT vs 35.4% oral corticoids
 - 24 +/- 20 dB vs 4.7 +/- 16 dB (p<0.05)
- Amarillo E, et al. Efficacy of intratympanic corticosteroid as a salvage treatment in idiopathic suddensensorineural hearing loss. *Acta Otorrinolaringol Esp. 2019*;70:207-214.
 - Observational study of 109 cases
 - Csystemic corticoids (7d)+ ITT if failure
 - PTA 7 d : 53 dB in control group vs 66 dB in ITT group (P<.01).
 - At 6 months, improvement of 10.8dB in ITTs vs 1.1dB in controls

 \Rightarrow ITT est effective in salvage cases if early applied

CONCLUSION

- In sudden SNHL
 - FIRST: confirm diagnosis and evaluate labyrinthine function alteration
 - AUDITORY TESTING
 - VESTIBULAR TESTING
 - Effective Search for etiology:
 - IMAGING: +++
 - BLOOD WORK
 - CARDIOVASCULAR CHECKING: MANDATORY IF BALANCE IMPAIRMENT
 - TREAT As Soon As Possible:
 - ORAL CORTICOIDS IF POSSIBLE (NO CONTRAINDICATION AT 1 MG/D/KG FOR 7 DAYS WITH SLOW REGRESSION
 - IF FAILURE: ITT WITH DXM (40MG/ML) 5 DAYS
 - IF SEVERE TO PROFOUND SNHL: COMBINED TREATMENT





STRATEGY IN CASE OF LIMITED RESOURCES: QUESTIONS TO AUDIENCE • FUNCTIONAL EXPLORATION: WHICH TYPE?

- CARDIOVASCULAR EXPLORATION: WHICH TYPE?
- IMAGING? WHICH TYPE?
- BLOOD WORK? WHICH TYPE?
- TREATMENT: ORAL OR ITT CORTICOIDS?



